CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Financial Statements and Exhibits

CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Financial Statements and Exhibits
Item 9.01

Story continues below

Financial Statements and Exhibits.

(d) Exhibits.

EX-99.1 2 cbio-ex991_6.htm EX-99.1 cbio-ex991_6.htm Exhibit 99.1 Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B   Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX — Current lower doses are predicted to achieve normal Factor IX levels   SOUTH SAN FRANCISCO,…
To view the full exhibit click here


Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

An ad to help with our costs